J. Med. Chem.
60, 4869–81.
Design and discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancers.
2017
Nishiguchi, G.A., Rico, A., Tanner, H., Aversa, R.J., Taft, B.R., Subramanian, S., Setti, L., Burger, M.T., Wan, L., Tamez, V., Smith, A., Lou, Y., Barsanti, P.A., Appleton, B.A., Mamo, M., Tandeske, L., Dix, I., Tellew, J.E., Huang, S., Mathews Griner, L.A., Cooke, V.G., Van Abbema, A., Merritt, H., Ma, S., Gampa, K., Feng, F., Yuan, J., Wang, Y., Haling, J.R., Vaziri, S., Hekmat-Nejad, M., Jansen, J.M., Polyakov, V., Zang, R., Sethuraman, V., Amiri, P., Singh, M., Lees, E., Shao, W., Stuart, D.D., Dillon, M.P. and Ramurthy, S.
Notes: The major goal of this study was to identify selective RAF inhibitors that would suppress the RAF-MEK-ERKK pathway. A NanoBiT® cRAF:bRAF interaction assay was used to study the potency of identified compounds to stabilize this dimer using dose-response assays in transfected HCT116 cells (4967)
Expand Full Notes »